Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib for advanced solid tumors
ChiCTR1900027697Phase 4Not yet recruiting
- Sponsor
- Inner Mongolia Autonomous Region Cancer Hospital
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in Non-hematologic malignancy, sponsored by Inner Mongolia Autonomous Region Cancer Hospital. Primary endpoint: Objective response rate. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR1900027697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027697.